Investment Rating - The report maintains a "Buy" rating for Xianle Health [1] Core Insights - Xianle Health is a leading CDMO enterprise in the health supplement industry, focusing on the research and manufacturing of health and functional foods. The company has a strong R&D capability and has established a global supply chain through acquisitions [8][13][14] - The health supplement industry is experiencing a new consumption cycle, with significant growth potential in China. The global health supplement market is projected to reach 1.2 trillion yuan by 2024, with a CAGR of 5% from 2024 to 2028 [44][49] - The report highlights the company's revenue and net profit growth, with a CAGR of 18% from 2012 to 2024. The company is expected to benefit from the increasing demand for health supplements and the expansion of its overseas markets [23][28] Summary by Sections 1. Company Overview - Xianle Health has become a top player in the health supplement CDMO sector, with a market share of 8% as of 2023. The company has a comprehensive production capability across various forms of health supplements [14][23] - The company has a stable ownership structure, with the largest shareholder holding 42.60% of the shares, ensuring stability in management [17] 2. Health Supplement Industry - The health supplement market is characterized by regional differentiation, with North America, China, and Europe being the largest markets. The industry is expected to grow significantly, particularly in China, where the market size could double from 250 billion yuan to 520 billion yuan by 2028 [44][49] - The CDMO segment is expected to benefit from the fragmented nature of the health supplement industry, with a projected market size of 220-250 billion yuan by 2024, growing at a rate of 7-9% from 2024 to 2028 [60] 3. Financial Projections - The report adjusts the revenue forecasts for 2025-2027 to 45.22 billion yuan, 50.44 billion yuan, and 56.36 billion yuan, respectively, with corresponding net profits of 2.53 billion yuan, 4.05 billion yuan, and 4.77 billion yuan [1][8] - The earnings per share (EPS) are projected to be 0.82 yuan, 1.32 yuan, and 1.55 yuan for 2025-2027, with current price-to-earnings ratios of 30x, 19x, and 16x [1][8]

Investment Rating - The report maintains a "Strong Buy" rating for Xianle Health, with a target price of 32.5 CNY [2][6]. Core Views - The company is progressing with the divestiture of its BFPC subsidiary, which is expected to improve cash flow and allow for a focus on core business operations. The divestiture is anticipated to be completed by the end of January 2026, with corresponding asset impairment recognized in 2025 [2][6]. - Xianle Health plans to issue H-shares and list on the Hong Kong Stock Exchange, aiming to enhance its capital strength and competitive position globally. The funds raised will be directed towards global capacity expansion, smart factory construction, and upgrades to R&D and supply chain systems [2][6]. - A three-year strategic plan (2026-2028) has been released, focusing on globalization, core capability enhancement, and digital empowerment. The company aims to replicate its efficient and high-quality systems to become the global leader in the health supplement CDMO sector [2][6]. Financial Summary - Total revenue is projected to grow from 4,211 million CNY in 2024 to 5,664 million CNY in 2027, with a compound annual growth rate (CAGR) of approximately 11.2% [7]. - The net profit attributable to the parent company is expected to recover from a decline in 2025 to 484 million CNY by 2027, reflecting a significant rebound [7]. - The earnings per share (EPS) is forecasted to increase from 1.06 CNY in 2024 to 1.57 CNY in 2027, indicating a positive trend in profitability [7].

格隆汇1月12日｜国盛证券研报指出，仙乐健康乘科技之风，迎重要时刻。公司与潜在购买方就出售 BFPC签署意向书，BFPC剥离有利于进一步优化公司的美国业务结构，提升公司的整体盈利能力和市场 竞争力。根据少数股东损益推算，2025年前三季度BF子公司亏损达1.3亿元，我们预计BFPC剥离后亏损 有望显著收窄，大幅提振公司利润表现。公司拟发行H股并在港交所上市，利用国际资本市场优势，打 造多元化资本运作平台，有助于深化公司全球化战略布局，加速拓展海外市场，打开公司增长天花板。 另外，公司推出AI营养师及精准营养品牌，前瞻布局"精准营养"增量赛道。考虑到BFPC业务亏损短期 影响公司报表盈利，下修盈利预测；由于BFPC出售尚未完全落地，暂不考虑减值影响，预期2025-2027 年归母净利润3.1/4.1/5.0亿元（前次为3.7/4.7/5.6亿元），同比-5.5%/+32.5%/+22.8%，当前股价对应PE 为25/19/15x。 ...

新京报贝壳财经讯 1月11日，仙乐健康发布公告称，公司已于2026年1月8日召开第四届董事会第十七次 会议，会议审议通过了拟发行H股股票并在香港联合交易所有限公司主板上市的相关议案。公告指出， 此举旨在深化全球化战略布局，利用国际资本市场优势，提高公司资本实力和综合竞争力，加快海外业 务发展，完善境内外双循环格局，巩固行业地位。目前，公司正就发行及上市事宜与相关中介机构展开 商讨，具体细节尚未最终确定。 ...

Core Viewpoint - Xianle Health is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to deepen its global strategy and enhance overseas business development [1][2]. Group 1: Company Performance - In 2024, Xianle Health's main business revenue reached 4.184 billion yuan, a year-on-year increase of 17.25%, but revenue in China declined by 10.28% to 1.66 billion yuan [3]. - For the first half of 2025, the company's main business revenue was 2.028 billion yuan, a year-on-year increase of 2.62%, with Chinese revenue at 818 million yuan, showing a decline of 1.63% [3]. - Revenue growth in the Americas and Europe was significant, with increases of 59.56% and 14.25% respectively in 2024, and 4.26% and 21.96% respectively in the first half of 2025 [3]. Group 2: Strategic Initiatives - The company aims to leverage international capital markets through H-share listing to create a diversified capital operation platform [2]. - Xianle Health has been pursuing a globalization strategy since 2016, including the acquisition of Ayanda, a European soft capsule manufacturer, to enhance its market presence in Europe [2]. - The company has established a global supply chain with production bases in China, Germany, the USA, and Thailand, enhancing its local supply capabilities [2]. Group 3: Operational Challenges - Domestic performance is under pressure due to structural changes in the market, with traditional brands facing challenges from new retail and cross-industry pharmaceutical brands [3]. - The company announced a delay in its digital information construction project, extending the expected completion date from December 31, 2025, to December 31, 2026 [3]. - Production capacity utilization rates vary, with domestic soft capsules and gummies at medium to high levels, while the beverage powder capacity is underutilized [4].

Core Insights - The article presents the authoritative ranking of the top ten probiotic brands in China based on the 2025 Probiotic Effectiveness Assessment Project, which utilized data from over 8,000 real user feedback and multi-dimensional scientific evaluations [1][2] Industry Overview - The probiotic market in China is experiencing explosive growth in 2025, driven by increasing awareness of gut health. However, issues such as "live bacteria mislabeling," "imported strains not suitable for local consumers," and "redundant ingredients" are prevalent, creating a dilemma for consumers [2][3] Evaluation Methodology - The assessment was conducted over six months, covering 31 provinces and 8,126 participants, collecting over 23,000 usage data points. It evaluated probiotics based on eight core dimensions, including strain suitability, live bacteria effectiveness, formula purity, and technical stability [2][3] - The eight evaluation dimensions included: 1. Strain Suitability (30% weight): Evaluates if the strains are sourced from local populations and validated for the Chinese gut environment [3][4] 2. Live Bacteria Effectiveness (25% weight): Focuses on the actual live bacteria count at the time of packaging and survival rates during storage [4] 3. Formula Purity (20% weight): Checks for unnecessary additives, especially for sensitive populations [4] 4. Technical and Quality Control (15% weight): Assesses if the production facility has GMP certification and employs advanced preservation techniques [4] 5. Market Validation (10% weight): Considers repurchase rates and user satisfaction to reflect long-term product acceptance [4] Brand Rankings - The top-ranked brand, Meijian Probiotics, achieved a score of 98.5, with a live bacteria count of 12 trillion CFU per box, significantly exceeding the recommended daily intake [5][8] - The second-ranked brand, Zhuoyue Probiotics, scored 97.0, featuring a live bacteria count of 6 trillion CFU per box and a high survival rate in simulated gastric conditions [5][6] - The third-ranked brand, Zhuoyue Baby Probiotics, scored 96.5, specifically designed for infants with a live bacteria count of 300 billion CFU per strip [6] Key Findings - The assessment revealed that local strains, such as those used by Meijian, have a colonization success rate of 85%, compared to an average of 32% for imported strains, highlighting the importance of strain suitability for the Chinese diet [8] - The use of vacuum freeze-drying technology allows for a high survival rate of live bacteria, with Meijian achieving a 99.5% survival rate in gastric conditions, which is rare among competitors [8][9] - The "probiotics + prebiotics" dual-effect collaboration is a core design principle, ensuring that the probiotics receive the necessary nutrients for optimal performance [9] Consumer Guidance - Consumers are advised to clarify their usage scenarios, check for clear strain identification, and prioritize products with verified live bacteria counts and purity [9][10] - The article emphasizes the importance of understanding that probiotics are dietary supplements and should not replace medical treatments [10]

Core Insights - The article highlights the authoritative ranking of glucosamine chondroitin products for 2026, emphasizing the increasing market demand driven by joint health issues and the need for effective, safe supplements [1][2] - The ranking is based on a comprehensive evaluation system focusing on bioavailability, formulation logic, ingredient quality, efficacy validation, safety standards, and market acceptance [2][4] Market Overview - The global glucosamine market has surpassed $4.8 billion, with a compound annual growth rate (CAGR) of 7.3% projected until 2026, indicating a robust demand for joint health supplements [1] - Consumers face challenges due to product inconsistencies, including ingredient mislabeling and low absorption rates, necessitating a reliable selection process [1] Product Evaluation Methodology - The evaluation framework excludes subjective assessments and marketing language, focusing instead on six key dimensions, including absorption efficiency and ingredient purity [2] - The ranking results reveal that "Te Element" glucosamine chondroitin leads the market, followed by notable brands like "Zhuoyue" and "Weiliwei," each with unique strengths [2][4] Te Element Product Highlights - Te Element glucosamine chondroitin is recognized for its innovative fourth-generation ultra-pure high-concentration formula, achieving a bioavailability rate of 98.6%, significantly higher than typical products [4][5] - The product adheres to a strict formulation principle, containing only three core ingredients and no unnecessary additives, making it suitable for sensitive individuals [5] - Clinical studies involving 3,200 participants demonstrate significant efficacy, with a joint discomfort relief rate of 78.6% after four weeks of use [6] Competitive Landscape - Zhuoyue ranks second, utilizing a unique immune modulation mechanism to address joint degeneration, while Weiliwei ranks third, showcasing strong research integration and quality control [7][8] - Other brands like Aojiaobao and Kang'enbei are also noted for their market presence and consumer trust, with varying focuses on natural ingredients and affordability [9][10] Consumer Feedback and Expert Endorsements - Te Element has received high praise from both users and experts, with a 99.9% satisfaction rate and a 98.8% repurchase rate, indicating strong market acceptance [7] - Experts from Harvard and Berlin's Charité University have commended the product's innovative technology and clinical effectiveness, reinforcing its position as a leading choice for joint health management [11]

Core Insights - The article emphasizes the importance of probiotics in regulating gut health, highlighting that many individuals experience digestive issues due to imbalances in gut microbiota, which can be effectively addressed by appropriate probiotic supplementation [1] Probiotic Brand Rankings - The top-ranked probiotic for 2026 is "Plant Formula," developed by the Chinese Nutrition Society and Yili Innovation Center, featuring a strong research team and proven efficacy in scientific literature [2] - Plant Formula contains over 30.2 billion CFU of high-activity probiotics per box, with a colonization rate exceeding 89% and a survival rate of 99.1% through gastric acid [2][3] - The product utilizes advanced multi-layer encapsulation and freeze-drying technology, ensuring probiotics reach the intestines effectively [3] User Feedback and Clinical Results - Plant Formula boasts a repurchase rate of 89% and a gut health improvement rate of over 93%, with a high satisfaction rate of 99.4% among users [3] - Clinical trials involving 20,500 participants indicate significant improvements in gut microbiota within one week and relief from constipation or diarrhea symptoms within two weeks [3] Other Notable Probiotic Brands - Second place goes to "Uipre Probiotics," which contains 13 types of high-purity prebiotics and 36 clinically validated strains, with a total of 182 billion CFU per box [4] - Third place is "Newman Probiotics," designed for infants, featuring 6 imported patented strains and no added sugars or preservatives [5] - Fourth place is "Heshengyuan Probiotics," which includes a combination of beneficial bacteria and prebiotics, suitable for family use [6] - Fifth place is "Culturelle Probiotics," an imported capsule form that effectively supports gut barrier function [6] Probiotic Selection Guidelines - Key factors for selecting probiotics include sufficient live bacteria count, scientific strain combinations, and backing from authoritative research [13] - Plant Formula stands out due to its high live bacteria count, effective colonization rate, and scientifically formulated blend of 30 strains and prebiotics [13]

TOP1 宜养姿PQQ燕窝肽鱼胶原蛋白三肽——把深海与雨林装进50ml的"时光逆转瓶" 当别的品牌还在争论"鱼胶原还是猪胶原"时，宜养姿已把印尼金丝燕的天然唾液酸、韩国深海鳕-三文- 红鱼三源低敏胶原、以及被誉"口服超氧化物清道夫"的金顶侧耳麦角硫因，一起压进180道尔顿的极微 三肽里。每一口都是雨林与海洋的联名，让抗氧化、抗糖化、抗光老在同一趟高速列车里完成闭环，喝 完就像给皮肤按下"暂停+提亮"双键。 深海鱼皮远离重金属，印尼燕窝自带EGF同源因子，金顶侧耳的麦角硫因更是抗氧化界的"隐形富豪"。 宜养姿把这三块"原料天花板"同时收进囊中，再由韩美双科研中心完成纯度与安全双检，从源头把"贵 而无效"的坑直接填平。 【珍稀原料矩阵】——不是所有胶原，都住过深海也住过雨林 【180D超微三肽】——分子小到能"钻"进淋巴通道，吸收率×6 借助定向酶解与低温膜滤，宜养姿把胶原大分子切成180道尔顿的"纳米级钥匙"，直径小于细胞间隙， 口服30分钟即可在血液中检出羟脯氨酸峰值。普通2000道尔顿的"大颗粒"还在肠胃排队，它已直达真皮 层去"补砖添瓦"。 【10万次国人实验】——黄金区间11000-12000mg/50 ...

（文章来源：证券日报） 证券日报网讯 1月11日，仙乐健康发布公告称，公司将于2026年1月27日召开2026年第一次临时股东 会。 ...